Amirian E Susan, Levy Julie K
Public Health & Healthcare Program, Texas Policy Lab, School of Social Sciences, Rice University, Houston, TX, USA.
Maddie's Shelter Medicine Program, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA.
One Health. 2020 Mar 27;9:100128. doi: 10.1016/j.onehlt.2020.100128. eCollection 2020 Jun.
Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and public health need for vaccine development and regulatory body approved therapies. In particular, the current coronavirus disease 2019 (COVID-19) pandemic has quickly intensified interest in developing treatment options to mitigate impact on human life. Remdesivir (GS-5734™) is a broad-spectrum antiviral drug that is now being tested as a potential treatment for COVID-19 in international, multi-site clinical trials. Currently available evidence about the antiviral effects of remdesivir against coronaviruses is primarily based on and studies (including some on a chemically related compound, GS-441524™), which have demonstrated largely favorable findings. As the pandemic progresses, information from human compassionate use cases will continue to accumulate before the clinical trials are concluded. It is imperative for public health practitioners and the One Health community to stay up to date on the most promising potential therapeutic options that are under investigation. Thus, the purpose of this review is to synthesize the knowledge to date about remdesivir as a therapeutic option for coronaviruses, with a special focus on information relevant to the One Health community.
近期与冠状病毒相关疾病的国际流行凸显了疫苗研发和监管机构批准疗法的迫切医学和公共卫生需求。特别是，当前的2019冠状病毒病（COVID-19）大流行迅速激发了人们对开发治疗方案以减轻对人类生命影响的兴趣。瑞德西韦（GS-5734™）是一种广谱抗病毒药物，目前正在国际多中心临床试验中作为COVID-19的潜在治疗药物进行测试。目前关于瑞德西韦对冠状病毒抗病毒作用的现有证据主要基于[具体研究1]和[具体研究2]（包括一些对化学相关化合物GS-441524™的研究），这些研究已显示出总体上有利的结果。随着大流行的发展，在临床试验结束之前，来自人类同情用药案例的信息将继续积累。公共卫生从业者和“同一个健康”群体必须及时了解正在研究的最有前景的潜在治疗方案。因此，本综述的目的是综合迄今为止关于瑞德西韦作为冠状病毒治疗选择的知识，特别关注与“同一个健康”群体相关的信息。
